Parental Burden and Quality of Life in 5q-SMA Diagnosed by Newborn Screening

Area of Science:

• Medical Genetics
• Pediatric Neurology
• Public Health

Background:

• Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder.
• Newborn screening (NBS) for SMA enables early detection and intervention.
• The psychosocial impact of NBS-detected SMA on families remains an area of investigation.

Purpose of the Study:

• To evaluate the psychosocial burden experienced by parents of children diagnosed with SMA through NBS.
• To assess the quality of life (QoL), satisfaction, and work/activity impairment in these families.
• To compare the psychosocial impact between families with treated versus untreated children.

Main Methods:

• A survey was conducted 1-2 years post-diagnosis in families identified via SMA NBS pilot projects in Germany.
• Three validated parent-related questionnaires assessed psychosocial burden, QoL, and work/activity impairment.
• Statistical analyses compared outcomes between families with children receiving SMN-targeted therapy and those on a wait-and-see strategy.

Main Results:

• Parents of children receiving SMN-targeted therapy reported significantly higher social burden and personal strain/worries about the future compared to those on a wait-and-see strategy.
• No significant differences in overall Quality of Life (QoL) were observed between treated and untreated groups.
• Fathers of treated children experienced greater negative impacts on work productivity and daily activities.

Conclusions:

• NBS for SMA has a substantial psychosocial impact on families, extending beyond diagnosis to treatment decisions and future concerns.
• The findings underscore the necessity for integrated, multidisciplinary care and support for parents.
• Understanding parental perspectives is vital for genetic counselors and NBS programs to develop proactive care plans addressing parental anxiety and uncertainty.